CPHI Milan 2024: Trends in Oral Solid Dosage Forms

Pharmaceutical Technology®Europe sat down with Uwe Hanenberg, Head of Product Implementation at Recipharm, to talk about key trends shaping the oral solid dosage market, including technology advances and industry investments.

Hanenberg sees the oral solid dosage market growing, in part by the aging population, as well as a trend toward reducing the number of suppliers and the creation of strategic partnerships. Oral biologics are a popular development in the industry, because of the easy method of administration, as well as the push for continuous manufacturing processes, according to Hanenberg.

Investment will continue in the oral solid dosage market, according to Hanenberg, pointing out the popularity of glucagon-like peptide-1 (GLP-1) diabetes and weight loss drugs. “There will come further big products. And that is certainly not to be executed on an existing tablet line or blister line,” says Hanenberg. “That is something where you need more investment … I expect to see announcement on investment in high-potent capabilities, especially in CDMO [the contract development and manufacturing organization] space, anything that is related to completion of offerings to reach an integrated solution, which means I expect a further consolidation of the CDMO market. Then I expect a very significant investment in continuous manufacturing. There are big companies who have a commitment to produce, in future, 50–80% of all new launches on continuous manufacturing.”

Click the above video to watch the full interview.

Visit Recipharm at Booth 7B2. CPHI Milan is being held from Oct. 8–10, 2024 in Milan, Italy.

About the speaker

Uwe Hanenberg, Head of Product Implementation, Oral Solid Dose
Dr. Uwe Hanenberg is Head of Product Implementation, Oral Solid Dose (OSD) at Recipharm. Uwe is responsible for implementing and executing the OSD Product Development strategy that assures science driven, timely development of new products or services. Uwe has 25 years of experience in the pharmaceutical industry with Bayer, Altana, Grünenthal and Catalent. He has held several leading positions in quality, manufacturing and packaging, product development, project management within the Science & Technology sphere. His areas of expertise are oral formulation development, oral manufacturing technologies, stick pack technologies and pharmaceutical contract services and project management.